Scientific Advisory Board

Joseph C. Glorioso III, Ph.D.
Scientific Advisor

Joseph C. Glorioso III, Ph.D. - Oncorus Scientific Advisory Board

Joseph C. Glorioso III, Ph.D.

Scientific Advisor

Benjamin tenOever
Scientific Advisor

Benjamin tenOever - Oncorus Scientific Advisory Board

Benjamin tenOever

Scientific Advisor

Thomas W. Dubensky Jr., Ph.D
Scientific Advisor

Thomas W. Dubensky Jr., Ph.D - Oncorus Scientific Advisory Board

Thomas W. Dubensky Jr., Ph.D

Scientific Advisor

Brian D. Brown, PhD.
Scientific Advisor

Brian D. Brown, PhD. - Oncorus Scientific Advisory Board

Brian D. Brown, PhD.

Scientific Advisor

Joseph C. Glorioso III, Ph.D. - Oncorus Scientific Advisory Board

Joseph C. Glorioso III, Ph.D.
Scientific Advisor

Dr. Glorioso began his academic career at the University of Michigan Medical School where he became Professor of Microbiology and Immunology and Assistant Dean for Research and Graduate Studies. In 1989, Dr. Glorioso moved to the University of Pittsburgh School of Medicine to become the William S. McElroy Professor of Biochemistry and Chairman of the Department of Molecular Genetics and Biochemistry, a position he held until 2009. He continues to be a professor in this department.

Dr. Glorioso has established a 40-year history of research related to the basic pathobiology, immunology and genetics of herpes simplex virus (HSV). His contributions to the field include defining antiviral immune responses to infection, the genetics of viral pathogenesis and latency, and mechanisms of viral infection. Furthermore, he has been a pioneer in the design and application of HSV gene vectors for the treatment of nervous system diseases such as peripheral neuropathies, chronic pain, and brain tumors. He continues to be a worldwide leader in the HSV gene vector field through the creation of innovative gene vectors and the development of manufacturing methods for human clinical trials.

Dr. Glorioso has served as a member of the Recombinant DNA Advisory Committee (RAC), NIH (1994-1996); NIH Steering Committee of the National Gene Vector Laboratory (NGVL) (1995-2006); Member, NIH Steering Committee of the National Gene Vector Biorepository (2006- ); Founder, Member of the Board of Directors, Treasurer, Vice President, President, American Society of Gene and Cell Therapy (ASGCT); President, Association of Medical School Microbiology and Immunology Chairs (1999); National Steering Committee for the American Alliance for Cancer Gene Therapy (2006-) and Chair of ACGT Scientific Advisory Board (2014-). Dr. Glorioso was elected Fellow of the American Society of Microbiology (1991); Vectors/Pittsburgh – Man of the Year in Technology (1996); Elected to Who’s Who in America (1999); Elected Fellow of the American Association for the Advancement of Science (2003); 2007 Elected American Men and Woman of Science, Awarded the Paradigm Builder Lectureship by International Society of Neuro-virology (2010) and Human Gene Therapy: Gene Therapy Pioneer Award (2014).

Dr. Glorioso founded the Nature Journal Gene Therapy where he served as editor for 22 years and he is a member of the editorial board of Molecular Therapy. Dr. Glorioso co-founded several biotech companies that include Genvec Inc., Nuvovec srl and most recently Switch Bio, a neuromodulation company and Oncorus, Inc. a Cambridge based company dedicated to the use of oncolytic HSV for immunotherapy of cancer.

Benjamin tenOever - Oncorus Scientific Advisory Board

Benjamin tenOever
Scientific Advisor

Benjamin tenOever completed his postdoctoral formation in Molecular Biology from Harvard University in 2007 after receiving his PhD in Medicine from McGill University in 2004. This training was subsequently applied to the study of host and pathogen interactions, with a focus on the molecular biology of virus infection. In August of 2007, Dr. tenOever joined the Icahn School of Medicine in New York as an Assistant Professor of Microbiology where he is now a Fishberg Professor of Medicine, and the Director of the Virus Engineering Center for Therapeutic and Research (VECToR). He is a 2008 Pew Scholar, a recipient of the 2009 Presidential Award in Science and Engineering, a 2010 recipient of the American Society of Microbiology Young Investigator Award, a 2011 Cozzarelli Prize winner, and he received the Burroughs Wellcome Award for his work regarding the pathogenesis of infectious disease. From 2012 to 2013, he was honored with Outstanding Young Investigator Awards from the American Society of Gene and Cell Therapy and the American Society of Virology. He was also named a finalist for the Vilcek Award for creative promise and served as a US Ambassador of Science in France as a Distinguished Chair of the Fulbright Commission in 2015/2016. Most recently he was honored with the Innovator Prize by the Pew Charitable Trust. The tenOever lab is interested in virus engineering and the development of new biological tools to ascertain the interplay between viruses and their hosts. More specifically, the lab focuses on what constitutes different cellular defense systems, how these systems have been shaped over time, and how viruses circumvent them and cause disease.

Thomas W. Dubensky Jr., Ph.D. - Oncorus Scientific Advisory Board

Thomas W. Dubensky Jr., Ph.D.
Scientific Advisor

Thomas W. Dubensky Jr., Ph.D. is the CEO of Tempest Therapeutics, a development-stage company this is advancing a pipeline of orally available first-in-class small molecule therapeutics which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. Prior to Tempest, Tom was the Chief Scientific Officer of Aduro Biotech, where he led the development of first-in-class STING (stimulator of interferon genes) agonists. Additionally, Tom played principal roles in leading discovery biology, development and clinical translation to immunotherapy settings utilizing multiple vector platforms, including plasmid DNA, intracellular bacteria, lentiviruses, Maloney retroviruses, alphaviruses and oncolytic adenovirus at several Biotech companies—Viagene, Chiron, Onyx and Cerus. Tom has an extensive publication and issued patent record. He received his BA in Bacteriology and Immunology from the University of California, Berkeley, and his PhD at the University of Colorado Health Sciences Center. He conducted his post-doctoral fellowship at Harvard Medical School in the Department of Pathology.

Brian D. Brown, PhD. - Oncorus Scientific Advisory Board

Brian D. Brown, PhD.
Scientific Advisor

Brian Brown is the Associate Director of the Precision Immunology Institute (PrIISM) and a Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. He has worked in the gene therapy and genetic engineering field for more than 20 years, and holds several licensed biotechnology patents, including for vector and virus targeting and for genomic sequencing technologies. His lab researches a broad area of investigation that spans immune oncology, molecular immunology, microRNA biology, and gene editing. His group uncovered a previously unrecognized pathway controlling the innate response to pathogen-associated nucleic acids and defined the transcriptional networks of dendritic cells. Brian also helped develop the foundational microRNA-based targeting technology used by Oncorus in their novel oncolytic viruses. A major effort of his lab is now focused on identifying the factors that direct the immune response against cancer in order to improve cancer immunotherapy.